Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken

Sachan, Swati; Ramakrishnan, Saravanan; Annamalai, Arun S.; Sharma, Bal Krishan; Malik, Hina; Saravanan, B. C.; Jain, Lata; Saxena, M.; Kumar, Ajay; Krishnaswamy, Narayanan

doi:10.1016/j.vaccine.2015.07.016

Cited by 36 publications

(28 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, the combination of R-848 withinactivated IBV vaccine showed higher antibody response than the vaccine alone group. These findings indicate the adjuvant capacity of R-848 with live as well as inactivated IBV vaccines in increasing the antibody response, which is supported by our earlier report on inactivated NDV vaccine in SPF chicken [24].…”

Section: Discussionsupporting

confidence: 86%

“…TLR 7/8 agonists like imiquimod and R-848 are FDA approved drugs for basal cell carcinoma, actinic keratosis and papilloma virus in the human [33][34][35][36]. Recently, we reported the enhanced antigen specific cellular as well as humoral immune responses in the chicken when resiquimod (R-848) was used with inactivated NDV vaccine resulting in complete protection against virulent NDV challenge [24]. Since the adjuvant potential is likely to vary with the type of vaccine, we studied the effect of R-848 with IBV vaccine.…”

Section: Discussionmentioning

confidence: 99%

“…Cellular immune response in the experimental birds was assessed by lymphocyte transformation test (LTT) and flow cytometry as reported earlier [24].…”

Section: Evaluation Of the Cellular Immune Responsementioning

confidence: 99%

“…Co-delivery of Norwalk VLPs with gardiquimod (TLR7 agonist) or CpG ODN (TLR9 agonist) produced strong systemic as well as mucosal immune responses in the mice [23]. Recently, we reported the adjuvant potential of R-848 in the chicken when used with inactivated NDV vaccine [24]. However, the effect of R-848 on the mucosal immune response is not explored in the chicken hitherto.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken

Matoo

Bashir

Kumar

et al. 2018

Microbial Pathogenesis

Self Cite

View full text Add to dashboard Cite

Adjuvant enhancing mucosal immune response is preferred in controlling many pathogens at the portal of entry. Earlier, we reported that a toll-like-receptor 7 (TLR7) agonist, resiquimod (R-848), stimulated the systemic immunity when adjuvanted with the inactivated Newcastle disease virus vaccine in the chicken. Here, we report the effect of R-848 when adjuvanted with live or inactivated avian infectious bronchitis virus (IBV) vaccines with special emphasis on mucosal immunity. Specific pathogen free (SPF) chicks (n = 60) were equally divided into six groups at two weeks of age and immunized with either inactivated or live IBV vaccine adjuvanted with or without R-848. Groups that received either PBS or R-848 served as control. A booster was given on 14 days post-immunization (dpi). R-848 enhanced the antigen specific humoral and cellular immune responses when co-administered with the vaccines as evidenced by an increase in the antibody titre in ELISA and stimulation index in lymphocyte transformation test (LTT) till 35 dpi and increased proportion of CD4 and CD8 T cells on 21 dpi in the flow cytometry. Interestingly, it potentiated the IgA responses in the tear and intestinal secretions when used with both live and inactivated IBV vaccines. The combination of IBV vaccine with R-848 significantly up-regulated the transforming growth factor beta 4 (TGFβ4) transcripts in the peripheral blood mononuclear cells (PBMCs) than that of the respective vaccine per se. An enhanced secretory IgA response is likely due to the up-regulation of TGFβ4, which is responsible for class switching to IgA. In conclusion, co-administration of R-848 with inactivated or live IBV vaccine enhanced the systemic as well as mucosal immune responses in the chicken.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

“…Cellular immune response in the experimental birds was assessed by lymphocyte transformation test (LTT) and flow cytometry as reported earlier [24].…”

Section: Evaluation Of the Cellular Immune Responsementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken

Matoo

Bashir

Kumar

et al. 2018

Microbial Pathogenesis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cytokines have been used as immune adjuvants to improve the immune response of the vaccine for years (Sachan et al . ). One of them, interleukin‐18 (IL‐18), originally called interferon‐γ (IFN‐γ)‐inducing factor, connects the innate and adaptive immune responses by increasing the production of IFN‐γ and then inducing Th1 immune responses (Okamura et al .…”

Section: Introductionmentioning

confidence: 97%

Construction of a novelDNAvaccine candidate targeting F gene of genotypeVIINewcastle disease virus and chickenIL‐18 delivered bySalmonella

Gao

Yang

et al. 2019

J Appl Microbiol

View full text Add to dashboard Cite

Aims Genotype VII Newcastle disease (ND) is one of the most epidemic and serious infectious diseases in the poultry industry. A novel vaccine targeting VII Newcastle disease virus (NDV) is still proving elusive. Methods and Results In this study, we constructed regulated delayed lysis Salmonella strains expressing either a fusion protein (F) alone under an eukaryotic CMV promoter or together with chicken IL‐18 (chIL‐18) as a molecular adjuvant under prokaryotic Ptrc promoter, named pYL1 and pYL23 respectively. Oral immunization with recombinant strains induced NDV‐specific serum IgG antibodies in both pYL1‐ and pYL23‐immunized chickens. The presence of chIL‐18 significantly increased lymphocyte proliferation in immunized chickens, as well as the percentages of CD3+CD4+ and CD3+CD8+ T cells in serum, even if a statistically significant difference did not exist. After a virulent challenge, pYL23 immunization provided about 80% protection at day 10 postinfection, compared with 60% of protection offered by pYL1 immunization and 100% protection in the inactivated vaccine group, indicating the enhanced immune response provided by chIL‐18, which was also confirmed by histochemical analysis. Conclusions Recombinant lysis Salmonella‐vectored DNA vaccine could provide us a novel potential option for controlling NDV infection. Significance and Impact of the Study This study took use of a regulated delayed lysis Salmonella vector for the design of an orally administrated vaccine against NDV.

show abstract

Biomedical Applications

Popot¹

2018

Membrane Proteins in Aqueous Solutions

View full text Add to dashboard Cite

Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken

Cited by 36 publications

References 44 publications

Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken

Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken

Construction of a novelDNAvaccine candidate targeting F gene of genotypeVIINewcastle disease virus and chickenIL‐18 delivered bySalmonella

Biomedical Applications

Contact Info

Product

Resources

About